A Phase Ib Study to Evaluate RO7198457, an Individualized Neoantigen Specific Immunotherapy (iNeST), in Combination With Atezolizumab▼ in Patients With Locally Advanced or Metastatic Solid Tumors
RO7198457 is a systemically administered RNA-lipoplex individualized neoantigen specific immunotherapy (iNeST) designed to stimulate T cell responses against neoantigens. A first-in-human Phase Ib study of RO7198457, in combination with the aPD-L1 antibody atezolizumab▼ is being conducted in patients with locally advanced or metastatic solid tumors. Safety, tolerability, pharmacodynamic activity, and preliminary anti-tumor activity are presented in this oral presentation.
You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.